Signpath Pharma, Inc. (SGTH) Financial Statements (2024 and earlier)

Company Profile

Business Address 3477 CORPORATE PARKWAY, SUITE 100
CENTER VALLEY, PA 18034
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2016
MRQ
12/31/2015
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 6927161,24132
Cash and cash equivalents 6927161,24132
Prepaid expense 5  
Total current assets: 6987161,24132
Noncurrent Assets
Property, plant and equipment   50
Other undisclosed noncurrent assets   (5) 
Total noncurrent assets:    0
TOTAL ASSETS: 6987161,24132
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including: 310448422894
Interest and dividends payable 1,730   
Accrued liabilities 8675  
Other undisclosed accounts payable and accrued liabilities (1,506)373422894
Derivative instruments and hedges, liabilities    5,687
Other undisclosed current liabilities    862
Total current liabilities: 3104484227,444
Noncurrent Liabilities
Total liabilities: 3104484227,444
Equity
Equity, attributable to parent, including: 388268820(7,412)
Preferred stock   11
Common stock 14141313
Common stock, share subscribed but unissued, subscriptions receivable (249)   
Additional paid in capital 13,94412,70010,1201,287
Accumulated deficit (15,052)(13,417)  
Warrants and rights outstanding  15,69915,84910,614
Other undisclosed equity, attributable to parent 1,731(14,729)(25,164)(19,325)
Total equity: 388268820(7,412)
TOTAL LIABILITIES AND EQUITY: 6987161,24132

Income Statement (P&L) ($ in thousands)

6/30/2016
TTM
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Revenues
(Other Income)
 24   
Gross profit: 24   
Operating expenses (1,647)(2,742)(1,954)(1,312)
Other undisclosed operating loss (24)   
Operating loss: (1,647)(2,742)(1,954)(1,312)
Nonoperating income (expense) 12(5)(2)1
Investment income, nonoperating  11 
Other nonoperating income (expense) 12(6)(3)1
Loss from continuing operations before equity method investments, income taxes: (1,635)(2,748)(1,956)(1,311)
Other undisclosed income (loss) from continuing operations before income taxes  (1)(1)0
Loss from continuing operations: (1,635)(2,748)(1,957)(1,311)
Loss before gain (loss) on sale of properties: (1,635)(2,748)(1,957)(1,311)
Net loss attributable to parent: (1,635)(2,748)(1,957)(1,311)
Other undisclosed net loss available to common stockholders, basic (761)   
Net loss available to common stockholders, diluted: (2,396)(2,748)(1,957)(1,311)

Comprehensive Income ($ in thousands)

6/30/2016
TTM
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Net loss: (1,635)(2,748)(1,957)(1,311)
Comprehensive loss, net of tax, attributable to parent: (1,635)(2,748)(1,957)(1,311)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: